Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1510 TRIANgLE: DCF induction + tri-modality vs definitive chemoradiotherapy in unresectable thoracic esophageal SCC
jRCTs031180181Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: overall survival. Started Mar 2018; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031180181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180181.